Non-biomarker list
150 Non-biomarkers
| ID | Biomarker | Application | Reference |
|---|---|---|---|
| 1 | Venous invasion (VI) | NA | Kirsch R et al. 2017 |
| 2 | Subjective estimation of the width of ablative margin | NA | Yedururi S et al. 2017 |
| 3 | Exposure to meat-derived carcinogens | Diagnosis | Ho V et al. 2017 |
| 4 | Preoperative Aspartate Aminotransferase-to-Platelet Ratio | Diagnosis | Amptoulach S et al. 2017 |
| 5 | PD-1/CD8 ratio | Prognosis | Shibutani M et al. 2017 |
| 6 | miR-141 | NA | Long ZH et al. 2017 |
| 7 | oxygen uptake efficiency slope | Diagnosis | Bongers BC et al. 2017 |
| 8 | Primary tumor location | Prognosis | Zhang RX et al. 2017 |
| 9 | Cancer stem cell-related gene expression | Prognosis | Varun V Prabhu et al. 2017 |
| 10 | Cytokeratin-based assessment of tumour budding | Prognosis | Viktor H Koelzer et al. 2017 |
| 11 | vessel distance inter-quartile range (IQR) | Diagnosis | Corvigno S et al. 2017 |
| 12 | net health benefit (NHB) score | NA | Ezeife DA et al. 2017 |
| 13 | α-taxilin | Prognosis | Kanamori A et al. 2017 |
| 14 | Preoperative lymphocyte to monocyte ratio | Prognosis | Peng J et al. 2017 |
| 15 | Homogeneous texture features | Prognosis | Chee CG et al. 2017 |
| 16 | Fractalkine (C-X3-C motif chemokine ligand 1) | Prognosis | Miranda DO et al. 2017 |
| 17 | Hepatic Parenchymal Heterogeneity | Prognosis | Han NY et al. 2017 |
| 18 | t response-related parameters such as depth of response (DpR) | Prognosis | Kadowaki S et al. 2017 |
| 19 | Fusobacterium nucleatum | Prognosis | Yamaoka Y et al. 2017 |
| 20 | the mesenterially perfused intestine model | NA | Dominik Schreiber et al. 2017 |
| 21 | Low folate metabolic stress reprograms DNA methylation-activated sonic hedgehog signaling | Treatment | Feng HC et al. 2017 |
| 22 | zebrafish larvae xenografts | Prognosis | Fior R et al. 2017 |
| 23 | DNA double-strand breaks | NA | Seiwert N et al. 2017 |
| 24 | brachytherapy techniques | Treatment | Rodriguez-Ruiz ME et al. 2017 |
| 25 | Weight loss | Prognosis | Kocarnik JM et al. 2017 |
| 26 | Tumor Necrosis Factor Alpha -Induced Protein 3 | Prognosis | Ishani Majumdar et al. 2017 |
| 27 | CUT-PCR to detect sequences with oncogenic mutations in the ctDNA of colorectal cancer | Diagnosis | Lee SH et al. 2017 |
| 28 | MRI tumour regression grade | Prognosis | Battersby NJ et al. 2017 |
| 29 | Blastocystis sp. infection | NA | Kumarasamy V et al. 2017 |
| 30 | Elevated mean platelet volume | Prognosis | Li N et al. 2017 |
| 31 | Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy | Prognosis | Markovina S et al. 2017 |
| 32 | Desmoplastic Pattern | Prognosis | Ueno H et al. 2017 |
| 33 | ratios of ALDH1B1 to ALDH1A1 | Diagnosis | Matsumoto A et al. 2017 |
| 34 | Neutrophil infiltration | Prognosis | Wikberg ML et al. 2017 |
| 35 | Lymph Node Size | Prognosis | Tanaka T et al. 2017 |
| 36 | activating transcription factor 6 (ATF6) | Diagnosis | Hanaoka M et al. 2018 |
| 37 | Trifluridine/Tipiracil , Regorafenib | Treatment | Moriwaki T et al. 2017 |
| 38 | Bone Morphogenetic Protein 3 | Diagnosis | Houshmand M et al. 2017 |
| 39 | Diffusion kurtosis imaging | Diagnosis | Liu H et al. 2017 |
| 40 | altered metabolites(mice) | Diagnosis | Li Y et al. 2017 |
| 41 | olive oil and omega-3 PUFAs | NA | Tutino V et al. 2017 |
| 42 | NSC49L | Treatment | Satya Narayan et al. 2017 |
| 43 | Alcoholic liver disease | NA | Ma AT et al. 2017 |
| 44 | ratio of (CAPN1 × CAPN2)/(calpastatin × CaM) | Diagnosis | Liu B et al. 2017 |
| 45 | combinations of cetuximab plus AZD5363 or everolimus, | Treatment | Kim JS et al. 2017 |
| 46 | [18F]Fluoromisonidazole PET | Prognosis | Puri T et al. 2017 |
| 47 | Ileal intubation | NA | Singh HK et al. 2017 |
| 48 | model of tumor response prediction | Prognosis | Santos MD et al. 2017 |
| 49 | Endocytoscopy | Diagnosis | Sako T et al. 2017 |
| 50 | lymph node sampling (LNS) and lymph node ratio (LNR) | Prognosis | Li Destri G et al. 2017 |
| 51 | a molecular marker of cell aging. | NA | Gil L et al. 2017 |
| 52 | systemic immune-inflammation index (SII) | Prognosis | Chen JH et al. 2017 |
| 53 | Circular RNA hsa_circ_0000745(gastric cancer) | Diagnosis | Huang M et al. 2017 |
| 54 | C-reactive protein-to-albumin ratio (CAR) | Prognosis | Ide S et al. 2017 |
| 55 | Waist circumference (WC)，body mass index (BMI) | Diagnosis | Gathirua-Mwangi WG et al. 2017 |
| 56 | lymphocyte-to-monocyte ratio | Prognosis | Zhao J et al. 2017 |
| 57 | Estimation of the future liver remnant function (eFLRF) | NA | Chapelle T et al. 2017 |
| 58 | the inferior mesenteric vein diameter | Prognosis | Akingboye AA et al. 2018 |
| 59 | Fecal C. symbiosum | Diagnosis | Xie YH et al. 2017 |
| 60 | Duodenal localization | Prognosis | Wilhelm A et al. 2017 |
| 61 | neutrophil-to-lymphocyte ratio (NLR) and modified Glasgow prognostic score (mGPS) | Prognosis | Kim IH et al. 2018 |
| 62 | liver-limited disease(LLD) | Prognosis | Holch JW et al. 2018 |
| 63 | mutant BRAF inhibitor PLX4720, | Treatment | Rohde S et al. 2017 |
| 64 | ratio of thioredoxin/Keap1 protein | Prognosis | Chang LC et al. 2017 |
| 65 | DKI metrics， K parameters | Prognosis | Cui Y et al. 2018 |
| 66 | the EMD/mesorectum ratio | Prognosis | Shen L et al. 2017 |
| 67 | serum neutrophil-to-lymphocyte ratio | Prognosis | Balde AI et al. 2017 |
| 68 | Scutellaria barbata D. Don | Treatment | Wei LH et al. 2017 |
| 69 | early morphological response | Diagnosis | Mazard T et al. 2017 |
| 70 | the hepatic margin | Prognosis | Makowiec F et al. 2018 |
| 71 | CD133-targeted oncolytic adenovirus | Treatment | Sato-Dahlman M et al. 2017 |
| 72 | Flt-1, the type 1 receptor for vascular endothelial growth factor A | NA | Huang Y et al. 2017 |
| 73 | Transanal total mesorectal excision (TaTME) | Treatment | de Lacy FB et al. 2018 |
| 74 | Naples Prognostic Score, Based on Nutritional and Inflammatory Status | Prognosis | Galizia G et al. 2017 |
| 75 | microsatellite instability | NA | Campanella NC et al. 2017 |
| 76 | miRNA ratio | Diagnosis | Jinhua Zhang et al. 2017 |
| 77 | Post-CRT endoscopic findings | Prognosis | Sohn DK et al. 2017 |
| 78 | Haralick's texture features | Prognosis | Caruso D et al. 2018 |
| 79 | Streptococcus sp. vt_162 | Diagnosis | Brim H et al. 2017 |
| 80 | fluorine-18-fluorodeoxyglucose (F-FDG) uptake of bone marrow (BM) on PET/computed tomography (PET/CT) | Prognosis | Lee JW et al. 2017 |
| 81 | The preoperative neutrophil to lymphocyte ratio | Prognosis | Song Y et al. 2017 |
| 82 | preoperative neutrophil to lymphocyte ratio | Prognosis | Song Y et al. 2017 |
| 83 | baseline Eastern Cooperative Oncology Group (ECOG)-performance status (PS) | Prognosis | Kim SW et al. 2018 |
| 84 | hyperthermia | Diagnosis | Kim SW et al. 2018 |
| 85 | Urine metabolomics | Prognosis | Dykstra MA et al. 2017 |
| 86 | Microsatellite Instability | Prognosis | Marginean EC et al. 2018 |
| 87 | Standardized Index of Shape by DCE-MRI and intravoxel incoherent motion-derived parameters by DW-MRI. | Diagnosis | Petrillo A et al. 2017 |
| 88 | platelet to lymphocyte ratio | Prognosis | Lu C et al. 2017 |
| 89 | serum bilirubin | Prognosis | Yang L et al. 2018 |
| 90 | early diarrhea and fecal volum | Prognosis | Zhou C et al. 2017 |
| 91 | complex microsatellite | Prognosis | Oncotarget et al. 2017 |
| 92 | high tumor mutational burden | Diagnosis | Pai SG et al. 2017 |
| 93 | sphincter preserving length (SPL) | Prognosis | Liu Z et al. 2018 |
| 94 | Breath Volatile Organic Compound Profiling | Treatment | Markar SR et al. 2017 |
| 95 | metabolic activity of adipose tissue | Prognosis | Yoo ID et al. 2018 |
| 96 | triple test | Prognosis | Muralee M et al. 2017 |
| 97 | Orientin | Treatment | Thangaraj K et al. 2017 |
| 98 | Lymphocyte-to-monocyte ratio | Prognosis | Deng YX et al. 2017 |
| 99 | Tumor Regression Grading After Preoperative Chemoradiotherapy | Prognosis | Fokas E et al. 2017 |
| 100 | Jolkinolide B | Treatment | Zhang J et al. 2017 |
| 101 | VPA and short-course radiotherapy plus capecitabine | Treatment | Terranova-Barberio M et al. 2017 |
| 102 | high fatty liver index | Diagnosis | Ze EY et al. 2018 |
| 103 | Hepatic progenitor cells | Prognosis | Delladetsima I et al. 2018 |
| 104 | the neutrophil-lymphocyte ratio (NLR) | Diagnosis | Riedl JM et al. 2017 |
| 105 | the neutrophil-lymphocyte ratio (NLR) or the lymphocyte ratio (LYMR) and tumor-infiltrating lymphocyte (TIL) count | Prognosis | Xiao B et al. 2017 |
| 106 | Fibrin-bearing microparticles | Prognosis | Mege D et al. 2017 |
| 107 | Tumor volume | Prognosis | Jiang Y et al. 2017 |
| 108 | early dynamic changes Contrast-Enhanced Ultrasound Quantification Criteria | Prognosis | Tranquart F et al. 2018 |
| 109 | Contrast-Enhanced Ultrasound Quantification Criteria | Prognosis | Tranquart F et al. 2018 |
| 110 | Axonal excitability changes and acute symptoms | Treatment | Heide R et al. 2018 |
| 111 | Metastasectomy for Tumor-Infiltrating Lymphocytes | Treatment | Crompton JG et al. 2017 |
| 112 | 11-PPI-Mod | Prognosis | Cao B et al. 2017 |
| 113 | Plasma Cell-Free Circulating DNA | Diagnosis | Agah S et al. 2017 |
| 114 | 11-PPI-Mod | Diagnosis | Cao B et al. 2017 |
| 115 | FOBT, colonoscopy | Diagnosis | Shin HY et al. 2017 |
| 116 | Circulating cell-free DNA (cfDNA) | Prognosis | Schou JV et al. 2018 |
| 117 | extra-mural vascular invasion (EMVI) and CpG island methylator phenotype (CIMP) | Prognosis | Kokelaar RF et al. 2018 |
| 118 | human growth hormone (hGH) | Prognosis | Wang JJ et al. 2017 |
| 119 | CEA/PCI | Prognosis | Kozman MA et al. 2018 |
| 120 | prognostic nutritional index (PNI) | Prognosis | Peng J et al. 2018 |
| 121 | transanal drainage tube | Treatment | Kawada K et al. 2017 |
| 122 | lymphocyte-to-monocyte ratio | Prognosis | Abe S et al. 2018 |
| 123 | Tumor-infiltrating Lymphocytes | Prognosis | Shibutani M et al. 2017 |
| 124 | Lymph node involvement | Prognosis | Dinaux AM et al. 2017 |
| 125 | Low Visceral Fat Content | Prognosis | Miyamoto Y et al. 2018 |
| 126 | Colonoscopies | Diagnosis | Chen S et al. 2017 |
| 127 | NMR-based urinary metabolomics fingerprinting | Diagnosis | Zhening Wang et al. 2017 |
| 128 | Ploidy and stroma-tumour fraction | Prognosis | Danielsen HE et al. 2018 |
| 129 | early morphological change (EMC) | Prognosis | Arai H et al. 2017 |
| 130 | Golgi pH homeostasis | Treatment | Kokkonen N et al. 2018 |
| 131 | Hyperglycemia combined Helicobacter pylori infection | Prognosis | Hu KC et al. 2017 |
| 132 | Extramural Venous Invasion | Prognosis | van Eeghen EE et al. 2017 |
| 133 | mean corpuscular volume (MCV) | Diagnosis | Ziai J et al. 2018 |
| 134 | total lesion glycolysis (TLG) | Diagnosis | Ince S et al. 2017 |
| 135 | smoking and metabolic syndrome | Prognosis | Chen DZ et al. 2018 |
| 136 | Clinicopathologic features | Prognosis | Hashmi AA et al. 2018 |
| 137 | clinical factors | Prognosis | Song JH et al. 2018 |
| 138 | Histopathological growth patterns | Prognosis | van Dam PJ et al. 2018 |
| 139 | FDG-PET/CT | Prognosis | Okuno T et al. 2018 |
| 140 | Patients' age, female sex, and T4 tumors | Prognosis | Emile SH et al. 2018 |
| 141 | antibody response to Streptococcus gallolyticus | Prognosis | Butt J et al. 2018 |
| 142 | eicosanoids | Diagnosis | Zhang J et al. 2017 |
| 143 | NDRG2low/Skp2high | Diagnosis | Shen L et al. 2018 |
| 144 | SATB2 | NA | Iwaya M et al. 2019 |
| 145 | TRF2/SULF2 expression | NA | Zizza P et al. 2019 |
| 146 | platelet size | NA | Barth DA et al. 2019 |
| 147 | LOF SNPs in FPR1, TLR3, or TLR4 | NA | Gray V et al. 2019 |
| 148 | MSI-L phenotype | NA | Torshizi Esfahani A et al. 2019 |
| 149 | BRAF mutation | NA | Chouhan H et al. 2019 |
| 150 | PD-L1 | NA | Berntsson J et al. 2019 |
